NPAT collapsed 76% and operating cash swung to -$69m despite 19% revenue growth

What changed

Reported revenue rose 18.8% to $664.2m, but almost the entire uplift is explained by the Dairyworks cheese/butter/ice-cream segment contributing $112.6m of consolidated revenue that was not in the HY20 base. Consumer-packaged infant formula volumes fell 16% to 18,085 MT, and cost of sales grew faster than revenue ($604.5m vs $476.4m), compressing gross margin from 14.8% to 9.0% – a 584 bps drop.

Earnings deteriorated sharply down the P&L: EBITDA –29% to $47.7m, operating profit –57.8% to $19.6m, PBT –77.1% to $8.5m and NPAT –75.7% to $6.4m. The PBT–NPAT gap is only 1.4 pp and the effective tax rate actually fell from 29.0% to 24.7%, so the operating read and reported NPAT tell the same story.

Cash flow deteriorated materially. Operating cash flow swung from +$12.2m to –$69.1m. With capex of $62.6m, pre-lease free cash flow was about –$131.7m versus –$75.2m in HY20. Inventory rose 32.6% to $406.4m and inventory days increased to 122.4 from 117.1. Gross borrowings climbed to $491.2m, net debt sits around $482.0m, and total equity jumped to $830.3m (from $519.6m) reflecting the equity raise that funded the Dairyworks transaction.

What matters

• Core margin compression is the dominant signal. Strip out the Dairyworks consolidation and revenue effectively went sideways while gross margin halved. The 16% fall in consumer-packaged infant formula – the high-margin product – is the most consequential operational disclosure in the release.
• Leverage has stretched against a weaker earnings base. Net debt of $482.0m against an HY21 EBITDA of $47.7m implies roughly 10x on the half-year run rate. Even on a second-half-weighted shape, the balance sheet is now carrying materially more debt into a period where the earnings trajectory is negative rather than neutral.
• Cash conversion has broken down. OCF/EBITDA ran at –144.8%, driven largely by inventory build and the receivables profile. This is the difference between a "soft profit half" and a "soft profit half that is also consuming balance-sheet capacity."

Expectations

No quantitative guidance or forward-work metric was disclosed. The only shape context is FY20 seasonality, where HY20 represented 43% of full-year revenue and 34.8% of full-year NPAT – i.e., the business is historically second-half weighted. Annualising HY21 revenue gives about $1.33b, only ~2% above FY20's $1.30b, which understates the true top-line trajectory because H2 has historically carried the heavier share.

The release does not support any view on whether H2 FY21 margins recover, because the three headwinds visible here – infant formula volume, inventory build, and cost-of-sales inflation – are not quantified as one-off versus structural. It does not support comfort on leverage either, absent a clear H2 EBITDA path.

Quality of result

Low-quality. The small reported NPAT of $6.4m is not helped by a favourable tax line, but it sits against a $69.1m operating cash outflow and a 32.6% jump in inventories, which argues that even the thin reported profit is partly carried by stock rather than converted to cash. Cash conversion deteriorated materially versus the prior half. The revenue headline flatters the underlying picture because roughly all of the 18.8% growth is acquisition-consolidation, not organic.

On the balance-sheet side, the equity increase reflects capital raising rather than retained earnings (ROE fell to 1.9% from 9.3%), and the modest $2.2m increase in cash masks an additional $40.6m of gross borrowings.

Unresolved

• How much of the 16% drop in consumer-packaged infant formula volume is demand, channel destocking, or specific customer programme timing, and is it recoverable in H2?
• What is the expected unwind path for the $406.4m inventory balance, and how much of the H1 cash outflow reverses in H2 versus persists?
• With net debt near $482m and leverage around 10x on half-year EBITDA, what are the covenant headroom and facility-maturity implications if H2 EBITDA does not step up materially?
• Prior-period segment splits were not supplied, so the organic revenue and margin path ex-Dairyworks cannot be measured precisely.
• Full EBITDA reconciliation and any non-recurring items were not disclosed in the supplied excerpt.

This briefing cannot assess the durability of the infant formula volume decline, the H2 margin trajectory, or covenant/liquidity headroom, because none of those items are quantified in the supplied data.

Key metrics

Segment breakdown

Analytical metrics

---

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.